These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 8972231

  • 1. Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability.
    Fukasawa K, Vande Woude GF.
    Mol Cell Biol; 1997 Jan; 17(1):506-18. PubMed ID: 8972231
    [Abstract] [Full Text] [Related]

  • 2. MAP kinase activation is essential for oncogenic transformation of NIH3T3 cells by Mos.
    Okazaki K, Sagata N.
    Oncogene; 1995 Mar 16; 10(6):1149-57. PubMed ID: 7700641
    [Abstract] [Full Text] [Related]

  • 3. Transformation-resistant mos revertant is unable to activate MAP kinase kinase in response to v-mos or v-raf.
    Topol LZ, Marx M, Calothy G, Blair DG.
    Cell Growth Differ; 1995 Jan 16; 6(1):27-38. PubMed ID: 7718484
    [Abstract] [Full Text] [Related]

  • 4. Comparative effects of insulin on the activation of the Raf/Mos-dependent MAP kinase cascade in vitellogenic versus postvitellogenic Xenopus oocytes.
    Chesnel F, Bonnec G, Tardivel A, Boujard D.
    Dev Biol; 1997 Aug 01; 188(1):122-33. PubMed ID: 9245517
    [Abstract] [Full Text] [Related]

  • 5. Mitogen-activated protein kinase activation resulting from selective oncogene expression in NIH 3T3 and rat 1a cells.
    Gallego C, Gupta SK, Heasley LE, Qian NX, Johnson GL.
    Proc Natl Acad Sci U S A; 1992 Aug 15; 89(16):7355-9. PubMed ID: 1323832
    [Abstract] [Full Text] [Related]

  • 6. Protein kinase C-zeta reverts v-raf transformation of NIH-3T3 cells.
    Kieser A, Seitz T, Adler HS, Coffer P, Kremmer E, Crespo P, Gutkind JS, Henderson DW, Mushinski JF, Kolch W, Mischak H.
    Genes Dev; 1996 Jun 15; 10(12):1455-66. PubMed ID: 8666230
    [Abstract] [Full Text] [Related]

  • 7. Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding.
    Fukasawa K, Zhou R, Matten WT, Armstrong AJ, Daar I, Oskarsson M, Sathyanarayana BK, Maclvor L, Wood TG, Vande Woude GF.
    Oncogene; 1995 Oct 19; 11(8):1447-57. PubMed ID: 7478569
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of v-raf-dependent c-fos expression and transformation by a kinase-defective mutant of the mitogen-activated protein kinase Erk2.
    Kortenjann M, Thomae O, Shaw PE.
    Mol Cell Biol; 1994 Jul 19; 14(7):4815-24. PubMed ID: 8007980
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of the Raf-1 kinase by cyclic AMP agonists causes apoptosis of v-abl-transformed cells.
    Weissinger EM, Eissner G, Grammer C, Fackler S, Haefner B, Yoon LS, Lu KS, Bazarov A, Sedivy JM, Mischak H, Kolch W.
    Mol Cell Biol; 1997 Jun 19; 17(6):3229-41. PubMed ID: 9154822
    [Abstract] [Full Text] [Related]

  • 10. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1.
    Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M.
    Mol Cell Biol; 1997 Sep 19; 17(9):5598-611. PubMed ID: 9271435
    [Abstract] [Full Text] [Related]

  • 11. Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13-acetate requires Raf and is necessary for transformation.
    Troppmair J, Bruder JT, Munoz H, Lloyd PA, Kyriakis J, Banerjee P, Avruch J, Rapp UR.
    J Biol Chem; 1994 Mar 04; 269(9):7030-5. PubMed ID: 8120067
    [Abstract] [Full Text] [Related]

  • 12. Deregulation of p53/p21Cip1/Waf1 pathway contributes to polyploidy and apoptosis of E1A+cHa-ras transformed cells after gamma-irradiation.
    Bulavin DV, Tararova ND, Aksenov ND, Pospelov VA, Pospelova TV.
    Oncogene; 1999 Oct 07; 18(41):5611-9. PubMed ID: 10523840
    [Abstract] [Full Text] [Related]

  • 13. Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation.
    Khosravi-Far R, White MA, Westwick JK, Solski PA, Chrzanowska-Wodnicka M, Van Aelst L, Wigler MH, Der CJ.
    Mol Cell Biol; 1996 Jul 07; 16(7):3923-33. PubMed ID: 8668210
    [Abstract] [Full Text] [Related]

  • 14. The Mos/MAP kinase pathway stabilizes c-Fos by phosphorylation and augments its transforming activity in NIH 3T3 cells.
    Okazaki K, Sagata N.
    EMBO J; 1995 Oct 16; 14(20):5048-59. PubMed ID: 7588633
    [Abstract] [Full Text] [Related]

  • 15. Prostaglandin A2 blocks the activation of G1 phase cyclin-dependent kinase without altering mitogen-activated protein kinase stimulation.
    Hitomi M, Shu J, Strom D, Hiebert SW, Harter ML, Stacey DW.
    J Biol Chem; 1996 Apr 19; 271(16):9376-83. PubMed ID: 8621603
    [Abstract] [Full Text] [Related]

  • 16. Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts.
    Tang Y, Chen Z, Ambrose D, Liu J, Gibbs JB, Chernoff J, Field J.
    Mol Cell Biol; 1997 Aug 19; 17(8):4454-64. PubMed ID: 9234703
    [Abstract] [Full Text] [Related]

  • 17. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling.
    Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW.
    Genes Dev; 1998 Oct 01; 12(19):3008-19. PubMed ID: 9765203
    [Abstract] [Full Text] [Related]

  • 18. Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53.
    Lee SW, Fang L, Igarashi M, Ouchi T, Lu KP, Aaronson SA.
    Proc Natl Acad Sci U S A; 2000 Jul 18; 97(15):8302-5. PubMed ID: 10890907
    [Abstract] [Full Text] [Related]

  • 19. Ras-dependent and -independent pathways target the mitogen-activated protein kinase network in macrophages.
    Büscher D, Hipskind RA, Krautwald S, Reimann T, Baccarini M.
    Mol Cell Biol; 1995 Jan 18; 15(1):466-75. PubMed ID: 7799956
    [Abstract] [Full Text] [Related]

  • 20. Mos and the cell cycle: the molecular basis of the transformed phenotype.
    Yew N, Strobel M, Vande Woude GF.
    Curr Opin Genet Dev; 1993 Feb 18; 3(1):19-25. PubMed ID: 8384034
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.